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The syndrome of disseminated  intravascular  coagulation  (DIC) 1 is a  recog- 
nized complication of acute hemolytic episodes in both man  (1-3)  and labora- 
tory animals  (4,  5) and has been induced experimentally in monkeys and dogs 
by infusion of autologous red blood cell stroma (6, 7). The mechanism of stroma- 
induced DIC may be analogous to the demonstrable procoagulant activity of 
red cell membrane phospholipids in vitro. However, an additional or alternative 
chain of events involving activation of the complement system is suggested by 
the well-studied  model of DIC,  the  Sanarelli-Shwartzman  reaction,  produced 
by two appropriately spaced intravenous injections of bacterial endotoxin. The 
recent work of Fong and Good (8) and Margaretten  (9) indicate a requirement 
for  platelets  and  an  intact  complement  system  for  endotoxin-induced  DIC. 
Complement activation by endotoxin proceeds primarily, if not entirely, via the 
recently  described  alternate  pathway  (10).  In  view  of  the  ultrastructural 
similarity  between  endotoxin  and  red  cell  stroma  (i.e.,  bilaminar  membrane 
[11])  and their ability to produce DIC, we have initiated  studies to determine 
whether red cell stroma is also capable of activating the alternate complement 
pathway and to attempt to relate this function to the sequence of events lead- 
ing to DIC. 
Materials and Methods 
Preparation of A utologous Red Cell 3troma.--Hemoglobin-free  red cell stroma was prepared 
from five human volunteers by a modification of a previously described method  (7). 50 ml of 
anticoagulated  whole blood was collected from each donor. The red cells were washed three 
times in cold 0.850-/0 saline with aspiration  of the buffy coat and upper 5% of red cells after 
each wash to minimize platelet and leukocyte contamination. Red cells were lysed by suspen- 
sion in 50 volumes of 20 mosmol phosphate buffer with gentle swirling for 1 h. Ghosts were 
separated  from supernatant  hemoglobin by centrifugation  at 7,000 X  g for 60 rain, resus- 
pended in 0.85% saline, and recentrifuged at 7,000 )< g for another  60 rain. The supernatant 
was aspirated, and cold 0.85% saline was added equal to the volume of ghosts. The suspension 
1  Abbreviations used in this paper: C3A, C3-Activator; C3PA, C3-Preactivator;  DIC, dis- 
seminated  intravascular  coagulation;  HTR,  hemolytic  transfusion  reaction;  PF-3, platelet 
factor 3. 
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was incubated for 12-16  h  at 4°C  to leach out remaining hemoglobin, and then centrifuged 
at 27,000 X  g for 30  rain.  The ghosts were suspended in an equal volume of 0.85%  saline 
and 1 ml aliquots were distributed to three 12  X  72 mm polypropylene test tubes. One tube 
was designated "autologous red cell ghosts." The second and third tubes, immersed in an ice 
water bath, were sonicated at 20,000 cps (Biosonik  III, Bronwill Scientific,  Rochester, N. Y.) 
for  I  rain  and 5 rain and designated "autologous red cell stroma,  1 rain" and "autologous 
red  cell stroma, 5  rain,"  respectively. 
This same procedure with the following  alterations was employed for the production of 
hemoglobin-containing RBC  stroma.  The  supernatant  hemoglobin  solution  produced  by 
osmotic lysis was concentrated by negative pressure ultrafiltration and centrifuged at 40,000 
X  g for 15 min to remove all stromal material. An equal volume of this hemoglobin solution 
was added to the autologous ghosts before sonication in place of the 0.85% saline. The total 
amount of hemoglobin added was calculated to correspond to that which had been contained 
in  the given volume of RBC  ghosts. 
Preparation of A utologous Platelet Stroma.--Human platelets were separated from 50 ml of 
anticoagulated whole blood on  a  Hypaque-Macrodex discontinuous gradient  (12),  washed 
four times in 0.85% saline, and sonicated for 5 rain at 20,000 cps as described above. The 
whole sonicate was centrifuged at 60,000 X  g for 30  rain and the sediment, designated "au- 
tologous platelet stroma," resuspended in 0.85% saline and kept at 4°C for 16 h before use. 
Incubation  of Stroma  with  Autologous  Serum.--O.02  ml  of each stroma preparation was 
incubated with 0.1 ml of fresh autologous serum at 37°C for 60 rain.  Controls consisted of the 
following: 0.1 ml aliquots of serum containing (a) 0.02 ml of saline subjected to the same con- 
ditions  (centrifugation, sonication, incubation)  as  the stroma preparations,  (b)  0.02  ml  of 
autologous platelet stroma, (c) 0.02  ml of intact autologous RBC's, and  (d)  0.02 ml of con- 
centrated hemoglobin, all incubated at 37°C for 1 h. As a positive control for activation of the 
alternate pathway, 0.02 ml of an inulin suspension (25 mg/ml in 0.5% saline)  was incubated 
with serum for 1 h at 37°(;.  All samples were stored at --75°C until ready for assay. 
Antiserum,--Antiserum to C3-Proactivator (C3PA)  was purchased from Behring Diagnos- 
tics, Woodbury, N.  Y. 
Immun°electr°ph°resis'--Immun°electr°ph°resis  was  carried  out  in  i%  agar  in  sodium 
barbital buffer, 0.05 M, pH 8.2, containing 0.01 M EDTA. 0.02 ml wells and 0.085 ml troughs 
were employed. The period of eleetrophoresis  was 3 h  at room temperature with a  current of 
5  mA  per  slide. 
RESULTS 
Immunoelectrophoresis.--Evidence for activation of the alternate complement 
pathway by autologous red cell stroma is presented in Figs. 1 and 2. In slide A 
of Fig.  1, the upper well contains serum incubated with inulin; the lower well 
contains control serum  (serum plus saline). The trough contains antiserum to 
C3PA.  The characteristic  beta  mobility of C3PA  in  the  control  and inulin- 
treated sample is evident. Activation of the alternate pathway with cleavage 
of C3PA  to  C3-Activatm  (C3A),  represented by an  additional precipitin arc 
with gamma mobility, is clearly seen in the inulin-treated serum. In slides B, 
C, and D the upper wells contain serum incubated with autologous RBC ghosts, 
1 rain  stroma,  and 5  rain  stroma,  respectively. The generation of C3A from 
C3PA is clearly seen in all three samples. Slide E  demonstrates the inability of 
concentrated autologous platelet stroma to effect the cleavage of C3PA, thus 
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FI6.1. Slides A-D demonstrate the generation of C3A from C3PA by inulin and autologous 
RBC membranes. Slide E  demonstrates lack of this activity in concentrated platelet stroma. 
Anode is to the right, cathode to the left. 
for the  C3A  generating activity of the RBC  stroma preparations.  Similarly, 
incubation of serum with intact autologous RBC's had no effect on C3PA. 
Fig. 2 demonstrates the effect of hemoglobin on stromal activation of C3PA. 
In slides A, B, and C (corresponding to B, C, and D of Fig. 1), hemoglobin shows 
a  mild potentiating effect on C3A generation. Slide D, in which concentrated 
hemoglobin was incubated with serum, demonstrates very slight generation of 
C3A.  This activity was most likely the result of a  small  quantity of stroma 
material  remaining  after  centrifugation  since  a  second  centrifugation  at 
40,000 X g for 15 rain removed it completely. Although there was a small degree 
of variation among the five individuals tested, all samples of RBC ghosts and 
sonicated ghosts were capable of generating C3A.  In no instance did platelet 
stroma or intact red cells produce this effect. 
DISCUSSION 
Acute  hemolytic episodes  in  both  man  and  laboratory  animals  are  often 
accompanied  by  coagulation  changes  ranging  from  mild  hypercoagulability 
(13,  14)  to overt disseminated  intravascular coagulation  (4,  15,  16).  DIC  in 
humans  has  been  associated  with  both  immune  (e.g.,  hemolytic transfusion 
reactions [1, 4])  and nonimmune (e.g.,  falciparum malaria [5]) hemolysis, sug- 
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Fro.  2.  Slides  A-C  demonstrate  that  hemoglobin is  ineffective in  inhibiting the  RBC 
stroma activity. In slide D,  stroma-free hemoglobin is incapable of generating C3A. 
factor  in  DIC  induction.  Studies in  laboratory  animals  have  strongly sup- 
ported  these  observations,  especially  with  the  development  of  a  hemolytic 
transfusion reaction (HTR) model in the Cynomolgus monkey (Macaca irus) 
(2, 16). Hemolytic antibody, prepared by immunization of donor monkeys with 
allogeneic RBC's, when infused into recipient monkeys as either whole plasma 
or the hemolytic IgG fraction, produces brisk hemolysis followed by laboratory 
and histopathologic evidence of DIC. Similar results are obtained by infusion 
of incompatible RBC's into an isoimmune recipient (3), a  situation analogous 
to the usual clinically encountere:t HTR. 
In both these models, hemolysis is  achieved by activation of the  classical 
complement  pathway  by  IgG  antibody fixed  to  RBC  membrane  antigens. 
Consequently, the mechanism for initiation of DIC in these models is difficult 
to assess in view of the known procoagulant activity of RBC membranes as well 
as  the  reported  ability of antigen-antibody complexes themselves  to  induce 
DIC  (17,  18). However, the  observation by Rabiner et  al.  (6)  and Birndorf 
et al. (7) that autologous RBC stroma itself is capable of producing mild DIC 
when infused into dogs and monkeys simplifies the problem since a complement- 
fixing antigen-antibody system, in the form of hemolytic antibody, is no longer 
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fore, appeared to be due to the known in vitro procoagulant activity of mem- 
brane phospholipids and seemed to offer an explanation for the occurrence of 
DIC with acute hemolysis in man. 
However, doubts concerning the ability of intravascular hemolysis per se to 
activate the coagulation system have been raised by Triantaphyllopoulos (19, 
20), who was able to nullify the in vitro procoagulant effect of RBC stroma by 
addition of purified hemoglobin. Since hemoglobinemia is a natural consequence 
of massive intravascular hemolysis, Triantaphyllopoulos's findings appear  to 
cast doubt on a  direct activation of the coagulation system in vivo by RBC 
membrane phospholipids. 
In the present study we have presented evidence for activation of the alter- 
nate complement pathway by autologous red cell membranes, which may pro- 
vide an alternative mechanism for hemolysis-initiated DIC. RBC ghosts soni- 
cated for 5 min at 20,000 cps, the form used by Birndorf et al. in their monkey 
model,  effectively cleaved  C3-Proactivator  (C3PA)  to  C3-Activator  (C3A). 
RBC  ghosts sonicated for 1 min as well as unsonicated ghosts were equally 
effective in generating C3A.  Intact RBC's, in contrast, failed to produce this 
effect. Moreover, the presence of free hemoglobin had no inhibitory effect on 
the stromal C3A generating activity, in contrast to its reported inhibitory effect 
on the in vitro procoagulant activity of RBC stroma. 
It is possible that trace amounts of platelet phospholipid contaminating the 
infused autologous RBC stroma preparation could account for the coagulation 
changes observed  by Birndorf et  al.  and  Rabiner  et  ah  However,  the  C3A 
generating activity of our RBC stroma preparations does not reside in a con- 
taminating platelet fraction as evidenced by the total inactivity of concentrated 
platelet stroma. 
The significance of our present finding that human autologous RBC stroma 
can activate the alternate complement pathway may lie in the recently recog- 
nized  interrelationships  between  the  complement  and  coagulation  systems. 
Zimmerman et al.  (21) have described prolongation of whole blood clotting 
times and decreased prothrombin consumption in a  rabbit strain genetically 
deficient in  C6.  The  addition  of  highly purified  C6  to  the  deficient blood 
corrected  the  coagulation abnormality. Further work  by these investigators 
(22) has demonstrated that known activators of the alternate pathway (endo- 
toxin,  staphylococcal  protein  A,  inulin,  immunoglobulin  aggregates)  are 
effective in accelerating clotting of normal rabbit blood but are ineffective in 
C6 deficient blood. Furthermore, Girando et al.  (23) and Lee et ah  (24) have 
reported that the thrombocytopenia and intravascular coagulation induced by 
infusion of thromboplastin into rabbits and mice is also dependent upon the 
complement  system.  These  findings  coupled  with  reports  that  substances 
like endotoxin cannot initiate DIC in animals rendered hypocomplementemic 
by  cobra  venom factor  (8)  demonstrate  a  functionally important interrela- 
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The nature of the interaction between these two systems is ill-defined al- 
though  evidence  suggests  that  platelets  may be  the  intermediary.  The  in- 
abilitv of endotoxin to produce DIC in rabbits rendered severely thrombocy- 
topenic by antiplatelet antibody (9)as  well as the ability of  platelet  factor 
3 (PF-3)  (25) and frozen-thawed platelets (26) to induce intravascular coagu- 
lation support this hypothesis. The interaction of complement with platelets 
in hemolysis-initiated DIC is currently under investigation in the Cynomolgus 
monkey model. Two proposed mechanisms for RBC stroma activation of the 
coagulation system are presented in Fig. 3--one involving direct activation by 
membrane phospholipids and the other requiring the interaction of activated 
complement components with platelets to effect the release of PF-3. Comple- 
ment-dependent release  of platelet constituents by soluble antigen-antibody 
complexes or particulate matter has been demonstrated in nonprimate species 
(27),  and a similar process might occur in primates. In addition, recent studies 
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FIG. 3. Proposed mechanisms  for the production of DIC by autologous  red cell stroraa. 
by Siraganian and Alexander (28) have demonstrated that platelet lysis with 
release of PF-3 can be produced in vitro by activation of the alternate  com- 
plement  pathway.  The  possibility  that  complement  activation  by  RBC 
stroma in the microenvironment of the platelet might lead to  the release  of 
PF-3  is  an  attractive  hypothesis.  However,  it  is  necessary to  repeat  these 
RBC stroma studies in hypocomplementemic and thrombocytopenic monkeys 
in  order to  define the  roles  of the proposed  intermediaries of DIC;  and  to 
assess  the relative significance of RBC membrane activation of the  coagula- 
tion system by direct  (i.e.,  membrane phospholipids)  and indirect (i.e.,  com- 
plement, platelets,  PF-3)  means. 
SUMMARY 
The  present  study  demonstrates  the  ability  of  human  autologous  RBC 
stroma to activate the alternate complement pathway (C3-Activator system, 
properdin  system),  as  evidenced  by  the  generation of  C3-Activator  (C3A) 
from  C3-Proactivator  (C3PA)  when  RBC  ghosts  and  sonicated  ghosts  are 
incubated  with  autologous serum.  Intact  RBC's,  hemoglobin,  and  concen- I'.  POSKITT 7  H.  FORTWENGLER,  JR.,  AND  B.  LUNSKIS  721 
trated  platelet  stroma,  on  the  other  hand,  are  inactive  in  this  regard.  We 
postulate that this in vitro activity of RBC strorna may occur intravascularly 
when  erythrocytes are  damaged by immune or nonimmune mechanisms. The 
ensuing interaction of activated complement components with platelets  lead- 
ing to release of platelet  factor three  (PF-3) may constitute a mechanism for 
activation  of the coagulation system during acute hemolytic episodes. 
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